CEASAR (Comparative Effectiveness Analysis of Surgery and Radiation for Localized Prostate Cancer) is an ongoing multi-site research study conducting long-term follow-up on more than 3,600 men in the United States diagnosed with localized prostate cancer between the years 2010 and 2012.

Funded in part by the Agency for Healthcare Research and Quality (AHRQ), the National Cancer Institute (NCI), and the Patient-Centered Outcomes Research Institute (PCORI), CEASAR is coordinated by Vanderbilt University Medical Center and has enrolled patients through the following six sites across the United States:

  • Emory University Rollins School of Public Health (Georgia Center for Cancer Statistics)
  • Keck School of Medicine of University of Southern California (Los Angeles Cancer Surveillance Program)
  • Louisiana State University Health Sciences Center (Louisiana Tumor Registry)
  • Rutgers Cancer Institute of New Jersey (New Jersey State Cancer Registry)
  • University of California, San Francisco (CaPSURE: Cancer of the Prostate Strategic Urologic Research Endeavor)
  • University of Utah (Utah Cancer Registry)

Who was eligible for enrollment?

At the time of enrollment, eligible participants must have met the following criteria:

  • Between the ages of 18-79
  • PSA <50 ng/ml at the time of diagnosis
  • Diagnosed with clinically localized disease
  • Must have completed the baseline survey within 6 months of diagnosis
  • Must not have begun or received treatment at the time of completion of the baseline survey
  • Must not have been diagnosed with any other malignancy (other than squamous or basal cell carcinoma of the skin) within 3 years of their prostate cancer diagnosis

Please note that CEASAR is currently in the long-term follow-up stage and is no longer enrolling new participants. 

What type of information is collected in CEASAR?

As the ongoing goal for CEASAR is to help learn more about what treatment works best, for which patients, and in whose hands, surveys are administered to enrolled participants at established time points. These surveys include questions relating to the participant's quality of life and other experiences related to their prostate cancer.

To date, participants have received surveys at five time points: a baseline survey completed within 6 months of their prostate cancer diagnosis, and subsequent follow-up surveys administered at 6 months, 1 year, 3 years, and 5 years post-baseline. Participants will begin to receive 8-10 year follow-up surveys in early 2020.

PDF copies of surveys administered at each time point are available here.